The ubiquitin-proteasome system (UPS) is a well-controlled, selective mechanism for intracellular protein degradation and turnover, and acts as a key regulator in cancer, CNS and many other diseases. Over the past few years, a new generation of inhibitors
and activators has been developed for disrupting protein-protein interactions and for hijacking the UPS for protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other small molecules have triggered targeted protein degradation
to seek out previously “undruggable” protein targets for drug discovery and therapeutic applications. However, challenges do exist in terms of specificity, stability, biodistribution and penetration of these molecules in vivo.
The conference on Ubiquitin-Induced Targeted Protein Degradation will bring together experts to discuss the key issues underlying targeted protein degradation as a new approach for therapeutic intervention.
Coverage will likely include:
- Hijacking the UPS using novel probes and chemical entities
- Recruiting deubiquitinases (DUBs), E2 and E3 ligases, and other proteins for target degradation
- Developing novel PROTACs and small molecules (IMiDs, CIDEs, and more) for protein degradation
- Strategies for characterization and optimization of degraders and ubiquitin inhibitors
- Assays for identifying the mechanism-of-action (MoA) of small molecule protein degraders
- Optimizing PROTACs and degrader molecules for clinical drug development
- Tackling challenges with specificity, stability, penetration and biodistribution and toxicity
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is December 18, 2020.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
We hope you can join us for this and the three concurrent day-and-a-half conferences during the first half of our 16th Annual Drug Discovery Chemistry event. Joining this virtual community in real-time allows you to ask questions of the speakers
and engage with colleagues. Plus, you can return later to view the concurrent presentations and Q&A panels that you missed, via On-Demand access.
For more details on the conference, please contact:
Tanuja Koppal, PhD
Senior Conference Director
Cambridge Healthtech Institute
Email: tkoppal@healthtech.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-628
Email: reymael@healthtech.com